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ABSTRACT
Katira gum, a natural polysaccharide resembles guar gum in chemical composition and is susceptible to degradation by 
colonic microflora. Azathioprine is used in the treatment of inflammatory bowel disease, ulcerative colitis and Crohn’s 
disease.  Present  investigation  was  undertaken  to  design  Katira  gum  oral  colon  targeted  matrix  tablets  containing 
azathioprine, in order to maximize its therapeutic efficacy. Central composite design (software design expert v. 8.0.7.1) was
employed to optimize the formulation for maximum drug release in colon.  The optimized batch tablets obtained  were 
further coated by Eudragit S100 to minimize the drug release in upper part of GIT. The uncoated matrix tablets released 
around 20-50% of the drug in the physiological environment of stomach and small intestine but released all its contents in 
the colon. The coated optimized formulation exhibited a release of only 5-35% in stomach and small intestine and almost all 
drug in simulated colonic dissolution media. The drug release kinetics followed Korsmeyer-Peppas model, indicating the 
drug release mechanism through combined diffusion and erosion mechanism. The results suggested that Katira gum can be 
a good carrier for colon targeting owing to its moderate viscosity, biocompatibility and biodegradability which could be 
successfully degraded by the microbial flora in the colon.
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INTRODUCTION
Targeted delivery to the colon holds promise for direct and 
more  effective  delivery  of  therapeutic  agents  for  the  local 
treatment  of gastrointestinal diseases such as colon cancer, 
irritable bowel syndrome, Crohn’s disease and for systemic 
delivery  of  proteins and  peptides.  A colonic  drug  delivery 
system is anticipated to safeguard the drug release during its 
transit in the upper gastrointestinal tract (GIT) and permit its 
release only in the colon. 
Azathioprine,  an  immunosuppressive  antimetabolite,  has 
been  implicated  in the  treatment  of  inflammatory  bowel 
disease 
[1], ulcerative colitis 
[2] and Crohn’s disease.
[3] The 
bioavailability of this drug upon oral ingestion is limited to 
an extent of 41-50%. 
A large number of bacterial enzymes, present in the colon, 
fulfill  their  energy  needs  by  fermenting  endogenous  and 
exogenous  substrates  such  as  carbohydrates  and  proteins, 
thus  causing  their  assimilation.
[4] Polysaccharides, 
commonly incorporated in pharmaceutical preparations, can 
be used as an alternative substrate for the bacterial enzymes 
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present  in  the  colon.  The  enzymes  act  on  the  matrices  of 
polysaccharides or the coatings and release the drug from the 
dosage form. Katira gum, a plant exudate, is one such natural 
polysaccharide obtained from Cochlospermum species.
Amongst  the  twenty  available  species  of  Cochlospermum, 
Cochlospermum religiosum is the only species that is found 
in India. It consists of the repeating units of d-galactose, d-
galacturonic acid and l-rhamnose in a molar ratio of 2:1:3.
[5]
Extensive research work has already been carried on other 
natural polysaccharides such as guar gum 
[6] and xanthan gum
[7], although very little literature is available on Katira gum as 
it is also liable for colonic degradation by microbial flora.
The present study was therefore undertaken to evaluate the 
therapeutic  potential  of  Katira  gum  in  colon  targeting  of 
model  drug  Azathioprine  with  formulation  optimization 
using central composite design (CCD) for the quantification 
of  effect  of  formulation  variables  on  the  performance  of 
dosage form.
MATERIALS AND METHODS
Materials:  Azathioprine  was  generously  gifted  by  Neon 
Laboratories  Ltd. (Mumbai,  India) and RPG  Life Sciences 
Ltd.  (Mumbai,  India).  All  the  chemicals  utilized  were  of 
suitable  analytical  grade  and  used as  and  when  required. 
Katira  Gum  was  procured  from  local  vendor  at  Hisar 
(Haryana)  and  authenticated  vide  reference  no. 
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Animals: Six Wistar Rats (150-200 g) were procured from 
the  Disease-Free  Small  Animal  House,  LLRUVS,  Hisar, 
Haryana. All these animals received proper human care. The 
experimental  protocol  was  approved  by  the  Institutional 
Animals  Ethics  Committee  (IAEC)  (Registration  number 
0436). 
Characterization of Azathioprine
Fourier Transform Infrared (FTIR) Analysis
The  pure  drug  Azathioprine  was  subjected  to  FT-IR 
spectroscopy  in  a  Fourier-Transform  Infrared 
Spectrophotometer  (FTIR  Spectrophotometer  Perkin-Elmer 
BX  II)  in  the  range  of  4000-500  cm
-1 using  KBr  pellet 
method.
Differential Scanning Calorimetric (DSC) Analysis
DSC  thermogram  of  Azathioprine  was  recorded  using 
Differential scanning calorimeter (Q10, TA Systems, USA). 
About  5  mg  of  samples  were  crimped  in  a  standard 
aluminium pan and heated in a temperature range of 25 to 
250°C  at  the  heating  rate  of  10°C  per  minute  in  nitrogen 
atmosphere (flow rate, 20 mL/min).
[8]
Characterization of Katira Gum
In addition to the FTIR and DSC analysis, Katira Gum was 
also characterized by the measurement of pH and viscosity of 
its 1% w/v solution. The swelling capacity of Katira gum was 
also  determined,  by  placing  1g  gum in  20 mL  water  in  a 
measuring  cylinder  for  24  hours.  Additional  80  mL  water 
was added in the cylinder after 2 hours. The swelling index 
of the gum was obtained using the formula: 
S.I= (V2-V1)/ V1
Where, S.I= Swelling Index; V1= Initial volume of gum; V2= 
Volume of hydrated gum
Experimental  Design:  In  the  present  study,  drug:polymer 
ratio (azathioprine:katira gum ratio), concentration of matrix 
forming  polymer  (methocel  K15)  and  intragranular  binder
(potato starch)  were used as independent variables at three 
levels (-1,0,+1) as formulation factors and the centre points 
(0,0,0)  were studied  in  quintuplicate.  The  software  Design 
Expert  v  8.0.7.1  was  employed  for  the  generation  and 
evaluation  of  central composite  statistical  experimental 
design, as shown in Table 1. Corresponding to the levels, -1, 
0, +1, the amount of Katira gum used was 25, 50 and 75 mg 
respectively. Similarly, an amount of 5, 10, 15 mg were used 
respectively in correspondence to the levels -1, 0, +1 for both 
methocel K15 and potato starch.
Preparation of matrix tablets of Azathioprine: The tablets 
were prepared using wet granulation method, in a Cadmach 
single  punch  tablet  compression  machine.
[9] Potato  starch 
was  incorporated  as  an  intragranular  binder  and  soluble 
starch as an extragranular binder. 
Determination  of  Flow  properties  of  granules:  Granules 
were  evaluated  for  their  bulk  and  tapped  density,  Carr’s 
index  and  Hausner’s  ratio,  which  are  essential  to  be 
determined, so as to avoid any trouble in their compression. 
Evaluation of matrix tablets: The physical parameters such 
as thickness, weight variation, hardness and friability were 
assessed  in  the  prepared  matrix  tablets.  To  obtain  the 
swelling index, accurately weighed tablets were placed in a 
petri dish containing 20 ml of phosphate buffer (pH 7.4) at 
room  temperature.  The  tablets  were  periodically  removed, 
blotted with blotting paper and again weighed. The swelling 
index was calculated using the equation:              
Swelling index= (Wt-W0)/W0
where, Wt= Weight of tablet at time t; W0= Weight of tablet 
at time t=0
In-vitro drug  release  study  of  matrix  tablets  of 
Azathioprine: The in-vitro dissolution studies were carried 
out in USP-II dissolution apparatus at a stirring speed of 50 
rpm in 900 mL of dissolution media maintained at 37±0.5°C. 
To  mimic  the  GIT  transit,  the  dissolution  was  carried  in 
different  bio-relevant  media  representing  pH  of  particular 
anatomical  region.  For  mimicking  the  gastric  fluid  in 
stomach,  the  dissolution  was  performed  in  0.1  N  HCl 
(pH=1.2)  for  two  hours,  in  phosphate  buffer  (pH=6.8)  to 
simulate  the  small  intestinal  fluid  for  three  hours  and  for 
another three hours in phosphate buffer (pH=7.4), simulating 
the  colonic  environment.  Sample  aliquots  withdrawn  at 
specific time intervals, were analyzed at 280 nm using UV-
Visible Double beam Spectrophotometer (Model-Systronics 
2203) against suitable blank.
Drug release studies of the optimized batch matrix tablets 
in the presence of rat caecal content: The susceptibility of 
the tablets to undergo degradation in the presence of colonic 
bacteria was assessed by conducting the drug release studies 
in  presence  of  rat  caecal  content.
[10]  Six  Wistar  rats 
(weighing 150-200 g) maintained  on normal diet  were fed 
with  Katira  gum (orally  1%  w/w)  for  15  days  in  order  to 
induce the microflora and enzymes. Rat caecal content was 
removed  and  a  4%  w/v  dispersion  in  phosphate  buffer 
(pH=6.8),  was prepared.
[11] It  was  used as  the  dissolution 
medium and conditions to mimic the anaerobic environment 
of colonic microflora were maintained by bubbling CO2 after 
every half  an hour and protected  from light.  The samples, 
withdrawn  at  specific  time  intervals  for  24  hours,  after 
suitable dilution, were analyzed at 280 nm using UV-Visible
spectrophotometer.
Eudragit  S100  coating  of  tablets  for  pH  dependent 
release: For minimizing  drug release in upper GIT, i.e. in 
stomach and small intestine, Eudragit S100 was selected as 
the  pH  dependent  coating  polymer.  A  10%  w/v  Eudragit 
S100 coating solution was prepared using isopropyl alcohol 
(IPA)  containing  3%  plasticizer- Polyethylene  glycol  400 
(PEG  400).
[12]  The  tablets  of  the  optimized  batch  were 
coated using this solution by dip coating method. 
Table 1: Experimental design (using design expert v 8.0.7.1)
Standard Run Drug:Polymer 
ratio
Conc. of matrix 
forming 
polymer
Conc. of 
intragranular 
binder
20 1 0.00 0.00 0.00
13 2 0.00 0.00 -1.68
10 3 1.68 0.00 0.00
3 4 -1.00 1.00 -1.00
7 5 -1.00 1.00 1.00
16 6 0.00 0.00 0.00
17 7 0.00 0.00 0.00
18 8 0.00 0.00 0.00
12 9 0.00 1.68 0.00
2 10 1.00 -1.00 -1.00
19 11 0.00 0.00 0.00
15 12 0.00 0.00 0.00
1 13 -1.00 -1.00 -1.00
9 14 -1.68 0.00 0.00
6 15 1.00 -1.00 1.00
4 16 1.00 1.00 -1.00
5 17 -1.00 -1.00 1.00
11 18 0.00 -1.68 0.00
14 19 0.00 0.00 1.68
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Table 2: Flow properties of granules
Formulation
Code
Bulk 
density
Tapped 
density
Carr’s 
Compressibility 
index
Hausner’s 
ratio
F1 0.60 0.69 13.04 1.28
F2 0.63 0.74 14.86 1.17
F3 0.62 0.72 13.88 1.16
F4 0.59 0.70 15.71 1.18
F5 0.57 0.71 19.71 1.22
F6 0.59 0.74 20.27 1.25
F7 0.55 0.67 17.91 1.21
F8 0.61 0.70 12.85 1.14
F9 0.54 0.68 20.58 1.25
F10 0.57 0.68 16.17 1.19
F11 0.61 0.69 11.59 1.13
F12 0.60 0.70 14.28 1.16
F13 0.61 0.75 18.66 1.22
F14 0.60 0.73 17.80 1.21
F15 0.58 0.69 15.94 1.18
F16 0.63 0.74 14.86 1.17
F17 0.62 0.72 13.88 1.16
F18 0.64 0.75 14.66 1.17
F19 0.57 0.70 18.57 1.22
F20 0.66 0.77 14.28 1.16
Table 3: Evaluation tests for matrix tablets
Formulation 
code
Weight 
variation
Thickness 
(mm)
Hardness 
(kg/cm
2)
Friability 
(%)
F1 149.48 ± 4.05 0.4±0.12 5.28 ± 0.14 0.6
F2 170.52 ± 5.36 0.5±0.15 5.24 ± 0.24 0.8
F3 157.73 ± 6.56 0.4±0.11 5.88 ±0.21 0.9
F4 171.19 ±7.33 0.3±0.18 5.8 ±0.2 0.9
F5 199.61 ± 5.96 0.6±0.2 5.92 ±0.21 0.6
F6 180.94 ± 7.38 0.4±0.21 5.18 ± 0.17 1.0
F7 166.87 ±6.43 0.6±0.13 5.08 ±0.07 0.6
F8 168.45 ±6.30 0.5±0.15 5.5 ± 0.14 0.7
F9 245.91 ± 2.54 0.3±0.16 5.14 ±0.10 0.5
F10 183.90 ± 6.73 0.5±0.08 5.4 ±0.17 0.8
F11 139.97 ± 5.73 0.5±0.12 5.66 ± 0.14 0.5
F12 203.17 ± 7.11 0.3±0.16 5.56 ± 0.18 0.7
F13 134.43 ± 6.64 0.2±0.18 3.08 ± 0.17 1.2
F14 117.35 ± 7.45 0.2±0.25 3.92 ± 0.28 1.4
F15 196.77 ± 5.77 0.6±0.22 4.98 ± 0.23 0.7
F16 147.53 ± 4.72 0.4±0.14 5.48 ± 0.20 0.6
F17 157.29 ± 4.74 0.4±0.18 5.52 ± 0.11 0.7
F18 160.03 ±5.79 0.3±0.11 5.2 ± 0.14 0.9
F19 166.01 ± 4.87 0.6±0.21 5.02 ± 0.11 0.8
F20 147.92 ± 3.88 0.5±0.09 4.74 ± 0.10 0.6
Drug Release kinetics: Data obtained from the in-vitro drug 
release  studies  of  matrix  tablets  of  optimized  formulation 
were  evaluated  using  various  kinetic  models  such  as  zero 
order,  first  order,  Higuchi  model  and  Korsmeyer-Peppas 
model.
RESULTS
Characterization of drug and polymer
FTIR spectrophotometric analysis: Figure 1 represents the 
FTIR spectrum of Azathioprine, Katira gum and optimized 
batch  matrix  tablets.  It  was  carried  out  to  evaluate  the 
possibility of interaction between the drug and the polymers 
used. Azathioprine depicted a number of characteristic peaks 
at 916, 1228, 1382, 1529, 1589, 3115  cm
-1 which may be 
attributed to the C-H deformation, C-N stretch, CH3 bend, C-
NO2 stretch,  C=N  and  N-H stretch  respectively.  The  most 
important peak obtained in the FTIR spectrum of Katira gum 
was found to be at 1332 cm
-1 which may be ascribed to CH3
bend.  The  spectra  of  Katira  gum  optimized  batch  matrix 
tablets  containing  Azathioprine  showed  all  these 
characteristic peaks of the drug and polymer indicating the 
absence of shifting or splitting in absorption peaks. Thus, it 
may be concluded that the chemical interaction between drug 
and other excipients did not take place during processing.
Differential  Scanning  Calorimetric  analysis: A 
comparison of the thermograms of pure drug, polymer and 
formulation has been displayed in Figure 2. In case of DSC 
thermogram of azathioprine, a sharp endothermic peak was 
observed at 268.77°C and an exothermic peak was observed 
at  263.39°C.  Thermogram  of  Katira  gum  showed  a  broad 
peak at 110.78°C; whereas, the optimized batch exhibited a 
broad  peak  at  100.64°C  and  a  sharp  peak  at  262.08  and 
297.65°C. In the thermogram of matrix tablet the peaks for 
azathioprine was observed, although its intensity was less.
Determination of pH of Katira Gum (1% w/v): The pH of 
1% w/v Katira gum was found to be 6.4, indicating slightly 
acidic nature of Katira Gum.
Determination of viscosity of Katira Gum: The viscosity 
of 1% w/v solution, measured  at 25±1°C using Brookfield 
DV-E viscometer, USA with spindle number 02, was found 
to be 66.4 cP and 62 cP at the speed of 100 and 60 rpm of the 
spindle  respectively.  Katira  gum,  in  contact  with  water, 
forms  a  thick  colloidal  hydrophilic  gel  which  on 
incorporation in the tablets, is responsible for the exhibition 
of  its  release  retardant  property.  Drug  release  from  such 
hydrophilic  gels  is  expected  by  diffusion  of  drug  solution 
through gel network.
Determination  of  swelling  capacity  of  Katira  gum: 
Swelling  index  of  gum  Katira  was  observed  to  be  26.66 
showing excellent swelling capacity by imbibition of water. 
High  swelling  capacity  suggests  its  possible  use  as  tablet 
binder, disintegrant etc.
Determination of flow properties of granules: Bulk density 
and tapped density were found ranging from 0.54 to 0.66 and 
0.67 to 0.77 respectively. Carr’s compressibility index (C.I) 
and Hausner’s ratio was found to fall in the range of 11.59 to 
20.58 and 1.13 to 1.28 respectively (Table 2). These results 
represent quite good flow properties of the granules. 
Evaluation of formulated matrix tablets of azathioprine: 
Since Katira Gum was found to have poor flow properties 
and was to be incorporated in the matrix tablets in a larger 
proportion,  the  tablets  were  prepared  by  wet  granulation 
technique using starch as a binder. The physical parameters, 
such as  thickness, weight  variation, friability and hardness 
were found to be within the permissible limits 
[13] for tablets 
(as depicted in Table 3).Table 4 highlights the swelling index 
of formulated matrix tablets. The degree of swelling of the 
prepared  matrix  tablets  was  observed  to  depend  on  the 
amount of Katira gum and HPMC. 
In-vitro dissolution study of formulated matrix tablets in 
different  bio-relevant  dissolution  media:  Katira  Gum 
matrix  tablets  released  about  20-50%  of  the  drug 
Azathioprine  in  the  physiological  environment  of  stomach 
and small intestine (pH= 1.2 and 6.4) as depicted in figure 3 
and figure  4  respectively.  The  matrix  tablets  released 
majority of its drug content in the physiological environment 
of colon (pH=7.4) as portrayed in figure 5. This indicates that 
Katira  gum  used  in  the  formulation  was  successfully 
degraded by microbes present in the colon. 
Solution of Numerical Optimization (using Design Expert 
v  8.0.7.1):  The  goal  of  optimization  was  to  minimize  the 
drug release in 2 hours and 5 hours (i.e. in stomach and small 
intestine) and maximizing the drug release in 8 hours (i.e. in
the  colon)  as shown  in  Table  5.  Based  on the  desirability 
approach  for  optimization,  the  solution  indicated  a 
drug:polymer  ratio  at  +2  level,  concentration  of  matrix 
forming  polymer  at  -0.97  level  and  concentration  of Singh et al. / Formulation Optimization for Colon Targeted Delivery of Katira Gum…..……
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intragranular binder at -2 level,  yielding 1.8% and 12.98% 
drug release in 2 and 5 hours respectively with entire drug 
release in 8 hours with desirability of 0.878. Cube plots for 
easier visualization of effect of three independent variables 
on response were generated (Figure 6), which indicated that 
concentration  of  intragranular  binder  be  minimized  to  -2 
level  and  matrix  forming  polymer  to  -0.27  level  with 
minimum drug:polymer ratio for maximum desirability.
Table 4: Swelling index of tablets
Time 
(hr) F1 F2 F3 F4 F5
0.5 260 155.1766 237.0006 94.23559 157.6609
1 263.7061 211.2667 256.051 163.7218 197.8039
1.5
Tablet  
disintegr
ated
270.7674 267.7475 172.8697 232.7886
2 - 483.0085 281.1812 240.3509 328.5495
4 - 563.8246 288.1297 399.0602 543.5138
6 - 594.2753 325.4198 424.3108 609.9081
8 - 597.9294 329.8205 429.1353 625.2809
10 - 600.3654 338.2745 461.0276 604.8008
12 - 607.1864 342.5594 465.3509 608.6823
Time 
(hr) F6 F7 F8 F9 F10
0.5 128.9692 419.0801 131.0667 98.36683 182.4401
1 202.0735 474.9574 191.4535 117.0854 224.9145
1.5 251.5995 496.2521 248.2221 167.9229 354.39
2 238.3294 479.2164 350.8422 183.3333 589.8518
4 277.6066 513.2879 423.2689 201.0469 699.3158
6 445.8531 536.0023 464.1298 280.8626 669.6693
8 557.9976 544.1794 468.1847 308.5846 680.4447
10 562.3223 490.5735 472.5515 318.4255 684.2075
12 566.4692 496.8768 477.4173 322.9481 694.4698
Time 
(hr) F11 F12 F13 F14 F15
0.5 283.0145 107.7756 251.7526 376.5144 119.4476
1 294.1086 150.5906 323.299 374.1845 162.5432
1.5 295.4858 175.2953 271.5464 396.5517 176.6398
2 298.3168 186.3189 264.811 366.6356 201.611
4 318.6687 232.3819 288.3849 390.028 230.7825
6 337.7965 348.622 270.1718 401.8639 327.2152
8 356.3887 360.3346 272.9897 409.972 332.5662
10 370.6963 385.1378 278.8316 425.3495 344.4764
12 380.3366 390.6496 287.7663 436.8127 350.6329
Time 
(hr) F16 F17 F18 F19 F20
0.5 191.0828 188.9026 190.0131 228.1081 72.10702
1 299.08 262.2072 448.0946 452.1922 91.23746
1.5 325.0531 277.0037 512.8121 413.2132 108.5619
2 304.034 290.7522 557.0302 478.3784 128.6957
4 311.6773 298.1504 570.1708 471.1712 140.8696
6 325.1946 320.9001 570.1708 494.955 132.3746
8 329.3701 325.6473 580.3548 498.3784 141.3378
10 335.8811 329.6547 596.452 508.4084 150.7023
12 340.9059 335.8816 606.1761 516.2162 155.5184
Study of release kinetics of optimized batch: Zero order 
was  found  to  be  the  best  fit  mathematical  model  for  the 
uncoated matrix tablets, suggesting that the drug released by 
diffusion  through  the  polymeric  gel  network.  The  drug 
release kinetics for the coated matrix tablets was observed to 
be best described by Korsmeyer-Peppas, indicating the drug 
release through a combination of diffusion as well as erosion 
mechanism. 
In-vitro dissolution  study  of  optimized  batch  matrix 
tablets:  During  the  in-vitro dissolution  of  the  optimized 
batch in rat caecal  medium, the tablet remained intact and 
slightly swollen for about 5 hours of the dissolution study. It 
was examined that with the amount of Katira gum increased 
in  the  formulation,  percentage  release  of  drug  decreased 
proportionally  and  vice-versa.  On  exposure  to  dissolution 
fluids, the gum gets hydrated and forms a viscous gel layer 
around  the  tablet,  slowing  down  further  seeping  of  the 
dissolution fluids towards the core of the tablets. The coating 
of the tablets with Eudragit S100 significantly reduced the 
release of drug (5-35%) in stomach and small intestine, thus 
allowing  a  successful  targeting  of  the  formulation  to  the 
colon.
Table 5: Solution of Numerical Optimization
Constraints 
name Goal Lower 
limit
Upper 
limit
Weig
ht
Importa
nce
A:Drug: Polymer 
ratio
Is in range -2 2 1 2
B: Conc. of 
matrix forming 
polymer
Is in range -2 2 1 1
C: Conc. of 
intragranular 
binder
Is in range -2 2 1 1
Cumulative drug 
release in 2 hrs
Minimize 1 12 1 3
Cumulative drug 
release in 5 hrs
Minimize 8 20 1 2
Cumulative drug 
release in 8 hrs
Maximize 95 100 1 5
N
o.
Drug:
poly
mer 
ratio
Conc. 
of 
matri
x 
formi
ng 
poly
mer
Con
c. of 
intr
a-
gra
nula
r 
bind
er
% 
Cum-
ulativ
e 
drug 
releas
e in 2 
hrs
% 
Cum-
ulativ
e 
drug 
releas
e in 5 
hrs
% 
Cum
-
ulati
ve 
drug 
relea
se in 
8 hrs
Desir-
ability
1 
soluti
on 
foun
d
1 2.00 -0.97 -
2.00
1.802
05
12.98
43 100 0.878 Select
ed
DISCUSSION
Azathioprine matrix tablets using Katira gum were prepared 
using Cadmach Single Punch Tablet Machine with varying 
ratio  of  drug:polymer,  matrix  forming  polymer  and 
intragranular  binder.  The  precompression  characteristics 
(Bulk density, Tapped density, Carr’s Compressibility Index 
and  Hausner’s  ratio)  were  evaluated.    These  parameters 
indicated good flow properties of the granules. 
The  matrix  tablets  were  successfully  formulated  by  wet 
granulation technique and were characterized by FTIR and 
DSC studies. The FTIR spectrum of pure azathioprine drug 
and  pure  polymer  (Katira  gum)  were  compared  with  the 
spectrum  of optimized  batch of azathioprine  matrix tablets 
prepared  using  Katira  gum.  The  presences  of  all 
characteristic peaks of Azathioprine and Katira gum in the IR 
spectrum  of  matrix  tablets  indicated  absence  of  chemical 
interaction  between  drug  and  other  excipients  during 
processing. 
DSC thermograms of pure drug Azathioprine, pure polymer 
Katira gum and optimized batch have been depicted in the 
overlay shown in figure 2. Peak intensity of azathioprine was 
less  as  compared  to  pure  drug  indicating  the  presence  of 
azathioprine in less crystalline form in the tablet which may 
be  attributed  to  wet  granulation  during  processing  which 
might have converted the drug from more crystalline form to 
amorphous  form.  All  other  exothermic  and  endothermic 
peaks  in  the  formulation  were  similar  to  that  in  the 
thermograms of pure drug and pure polymer, thus proving Singh et al. / Formulation Optimization for Colon Targeted Delivery of Katira Gum…..……
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Fig. 1: FTIR spectrum of (a) Azathioprine (b) Katira Gum (c) Optimized batch matrix tablets
Fig. 2: Overlay of DSC analysis of azathioprine, Katira gum and optimized batch formulationSingh et al. / Formulation Optimization for Colon Targeted Delivery of Katira Gum…..……
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Fig. 3: In-vitro dissolution study of prepared matrix tablets in dissolution medium having pH=1.2
Fig. 4: In-vitro dissolution study of prepared matrix tablets in dissolution medium having pH=6.8Singh et al. / Formulation Optimization for Colon Targeted Delivery of Katira Gum…..……
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Fig. 5: In-vitro dissolution study of prepared matrix tablets in dissolution medium having pH=7.4
Fig. 6: Model graphs of cumulative drug release in 2 hrs, 5 hrs and 8 hrs
the absence of any chemical interaction between the drug and 
other excipients.
The tablets were evaluated for various physical tests such as 
weight  variation,  thickness,  hardness  and  friability,  which 
conformed  to  the  prescribed  limits.   The  effect  of  various 
formulation variables like drug:polymer ratio, the amount of 
matrix  forming  polymer  and  the  amount  of  intragranular 
binder was evaluated. 
The  in-vitro dissolution  studies  of  the  prepared  tablets, 
carried out in different bio-relevant media (pH=1.2; pH=6.8 
and pH=7.4) showed the maximum percentage drug release 
in the colonic conditions but a small percentage of the drug 
was also observed to be released in the stomach and small 
intestinal  pH.  The  criteria  chosen  to  optimize  the  tablet 
formulation  constraints  viz.  drug:polymer  ratio,  amount  of 
matrix  forming  polymer  (methocel  K15)  and  intragranular 
binder (potato starch) were percent drug release in 2 hrs, 5 
hrs  and  8  hrs.  The  desirability  function  in  optimizing  the 
formulation with an importance value of 5 was to minimize 
the drug release in 2 hrs and 5 hrs; and maximize the drug 
release  in  8  hrs,  i.e.  the  tablet  must  release  all  its  drug 
contents in colon. The level of constraints that guarantee such 
a  response,  obtained  using  the  software  Design  Expert  v 
8.0.7.1, were drug:polymer ratio (2), methocel K15 (-0.97) 
and potato starch (-2.00). The optimized batch formulation 
was  prepared  and  was  selected  for  the  enteric  coating  of 
matrix  tablets  using  Eudragit  S100  to  minimize  the  drug 
release in upper GIT and for the evaluation of the percentage 
drug release in the  presence  of rat  caecal contents.  It  was 
observed that the tablet remained intact in the stomach and 
small intestine but released all its drug content (~100%) in 
the microbial environment, mimicking the colon. Zero order 
drug release was found to be the most suitable best fit for 
uncoated matrix tablets whereas the release kinetics of coated Singh et al. / Formulation Optimization for Colon Targeted Delivery of Katira Gum…..……
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matrix  tablets  was  best  described  by  Korsmeyer-Peppas 
model, suggesting the drug to be released by diffusion from 
polymeric gel network as well as by erosion mechanism from 
the coated tablets. 
Thus, the present study unraveled the effect of formulation 
variables  on  the  drug  release  from  the  matrix  tablets  in 
different  physiological  environment  of  stomach,  small 
intestine and colon. The results of this investigation clearly 
demonstrate that the optimized formulation of matrix tablets 
using  Katira  gum  is  capable  of  successfully  targeting  the 
drug  Azathioprine  to  the  colon  by  the  combination  of  pH 
dependent  and  microbially  triggered  approach  for  the 
efficient treatment of inflammatory bowel disease, Crohn’s 
disease  and  ulcerative  colitis.  The  present  research  work 
offers immense scope for further exploitation of Katira gum 
in future for targeting of other drugs to the colon.
ACKNOWLEDGEMENTS
The  authors  greatly  acknowledge  Neon  Laboratories  Ltd. 
(Mumbai,  India)  and  RPG  Life  Sciences  Ltd.  (Mumbai, 
India) for providing gift sample of azathioprine. The authors 
also  express  their  sincere  thanks  to  All  India  Council  of 
Technical Education, New Delhi for financial support.
REFERENCES
1. Dayharsh GA, Loftus EV, Sandborn WJ, Tremaine WJ, Zinsmeister 
AR,  Witziq  TE,  Macon  WR,  Burgart  LJ.  Epstein-Barr  virus-
positive lymphoma  in patients with imflammatory bowel disease 
treated with azathioprine or 6-mercaptopurine. Gastroenterol. 2002; 
122:72-77.
2. Ardizzone  S,  Molteni P, Imbesi  V, Bollani  S, Bianchi  Porro  G,
Molteni F. Azathioprine in steroid-resistant and steroid-dependent 
ulcerative colitis. J Clin Gastroenterol. 1997; 25:330-333.
3. Lewis  JD,  Schwartz  JS,  Lichtenstein  GR.  Azathioprine  for 
maintenance of remission in Crohn’s disease: Benefits outweigh the 
risk of lymphoma. Gastroenterol. 2000; 118:1018-1024.
4. Van den Mooter G, Kinget R. Oral colon-specific drug delivery- A 
review. Drug Deliv. 1995; 2:81-93.
5. Ojha AK, Maiti D, Chandra K, Mondal S, Das D, Roy SK, Ghosh 
K,  Islam  SS.  Structural  assignment  of  a  heteropolysaccharide 
isolated from the gum of Cochlospermum religiosum (Katira Gum). 
Carbohydr Res. 2008; 343:1222-1231.
6. Chaurasia M, Chourasia MK, Jain NK, Jain A, Soni V, Gupta Y, 
Jain SK. Cross-linked guar gum microspheres: A viable approach 
for  improved  delivery  of  anticancer  drugs  for  the  treatment  of 
colorectal cancer. AAPS Pharm Sci Tech. 2006; 7:E143-151.
7. Alvarez-Mancenido  F,  Landin  M,  Martinez-Pacheco  R.  Konjac 
glucomannan/xanthan  gum  enzyme sensitive  binary  mixtures  for 
colonic drug delivery. Eur J Pharm Biopharm. 2008; 69:573-581.
8. Rajera R, Nagpal K, Singh SK, Mishra DN. Toxicological study of 
the Primaquine phosphate loaded chitosan nanoparticles in mice. Int 
J Biol Macromol. 2013; 62:18-24.
9. Bharaniraja  B,  Kumar  KJ,  Prasad  CM,  Sen  AK.  Different 
approaches of Katira  gum formulations for colon targeting. Int J 
Biol Macromol. 2011; 49:305-310.
10. Gauri  B,  Nagpal  L,  Singh  SK.  Formulation  and  Gamma 
Scintigraphic Evaluation of Colon targeted drug delivery systems of 
tinidazole in healthy human volunteers. J Pharm Biomed Sci. 2011; 
7:1-9.
11. Sinha VR, Mittal BR, Kumria R. In-vivo evaluation of time and site 
of  disintegration  of  polysaccharide  tablet  prepared  for  colon-
specific drug delivery. Int J Pharm. 2005; 289:79-85.
12. Purushothaman M, Vijaya RJ. Formulation optimization and release 
kinetics of tinidazole matrix, compression and spray coated tablets: 
effect  of  organic  acid  on  colon  targeted  drug  delivery  systems. 
JITPS. 2010; 1:18-32.
13. Banker GS, Anderson NR. The Theory and Practice of Industrial 
Pharmacy. Edn 3, Varghese Publishing House, Bombay, 1987, pp. 
296-302.